Past event: Superbugs & Superdrugs USA 2018 Conference

Antimicrobial resistance, leading to the development of superbugs, is a major threat to public health and continues to increase as a problem, due to continued misuse of antibiotics. With pharmaceutical companies showing less focus on the development of new antibiotics, several incentive initiatives have been set up - CARBX, BARDA, IMI (EU) - in order to encourage reinvestments.

To address the ever-growing need of informative and thought-provoking discussions, Superbugs & Superdrugs USA conference will offer a jam-packed agenda with presentations from key industry leaders and up-and-coming thinkers, within the field.

This years' Superbugs &Superdrugs USA conference programme will help participants to learn about pathogen focused drug development; discover the best methods to overcome bacterial resistance through novel modes of action; discuss the state of developments within the antifungal space; develop an understanding of funding opportunities which support antibacterial research and development; gain insight into new techniques through case-study examples of rapid diagnostic methods currently being used within the field, making this event the perfect platform to strengthen knowledge in key principles.

Benefits of Attending

By attending our 3rd annual Superbugs & Superdrugs USA event, not only would you benefit from the knowledge delivered through range of thought-provoking presentations, by experts at the forefront of the field; but you would also receive the opportunity to interact with and exchange ideas with decision makers from all of the different facets of the industry - from research to commercial providers and regulatory bodies

This years' Superbugs & Superdrugs USA Conference will help you to:

• Gain insight into Diagnostic Technologies being used in the field and the futuristic developments which could be implemented.
• Network with key industry leaders and benefit from though provoking discussions
• Hear from the main regulatory bodies to advise on guidelines surrounding funding and development
• Listen to up-and-coming companies, developing novel approaches to circumvent antibacterial resistance
• Discover new approaches of anti-fungal development

Plus Two Interactive Half-Day Post-Conference Workshops | Wednesday 14th November 2018

Workshop A: Rapid diagnostics for drug resistance: Are we there yet?
Workshop Leader:  David Perlin, Executive Director & Professor, Public Health Research Institute, Rutgers University
08.30 - 12.30

Workshop B: Avoiding the post antibiotic era: the challenges and solutions to successful commercialisation of new antibiotics
Workshop Leaders:  Adam Woodrow, CCO, Parateck
David Findlay, Managing Director, Morton Findlay and Associates Ltd